CBR antimicrobials alter coupling between the bridge helix and the β subunit in RNA polymerase.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24598909.
- Also identified by DOI 10.1038/ncomms4408 and PMC identifier 3959191.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bacterial RNA polymerase (RNAP) is a validated target for antibacterial drugs. CBR703 series antimicrobials allosterically inhibit transcription by binding to a conserved α helix (β' bridge helix, BH) that interconnects the two largest RNAP subunits. Here we show that disruption of the BH-β subunit contacts by amino-acid substitutions invariably results in accelerated catalysis, slowed-down forward translocation and insensitivity to regulatory pauses. CBR703 partially reverses these effects in CBR-resistant RNAPs while inhibiting catalysis and promoting pausing in CBR-sensitive RNAPs. The differential response of variant RNAPs to CBR703 suggests that the inhibitor binds in a cavity walled by the BH, the β' F-loop and the β fork loop. Collectively, our data are consistent with a model in which the β subunit fine tunes RNAP elongation activities by altering the BH conformation, whereas CBRs deregulate transcription by increasing coupling between the BH and the β subunit.
Medical subject headings
- Amidines
- Anti-Infective Agents
- DNA-Directed RNA Polymerases
- Hydroxylamines